Stoke Therapeutics, Inc.
STOK· Nasdaq
Released Aug 10, 2021, before the open
10-Q filed Aug 10, 2021, 41 days after period end · 0001564590-21-043072
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Net Income | -$21.97M | -$12.96M | -$7.82M | -$3.01M |
| EPS Diluted | -$0.60 | -$0.39 | -$1.54 | -$4.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Stoke Therapeutics, Inc. · CIK 1623526 · Engraved from SEC EDGAR